<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">yYnv9S4Fw8DnWghK6q7KwrQ</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2020000500001</article-id>
      <article-id pub-id-type="publisher-id" specific-use="previous-pid">S0066-782X2019005022105</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20180130</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Syncope as a Phenotypic Expression of Hereditary Transthyretin Amyloidosis Val142Ile (Val122Ile)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2814-8395</contrib-id>
          <name>
            <surname>Nunes</surname>
            <given-names>N&#225;gela S. V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Jo&#227;o Paulo Moreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Fernanda Salom&#227;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2791-8375</contrib-id>
          <name>
            <surname>Nacif</surname>
            <given-names>Marcelo Souto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dominato</surname>
            <given-names>Joelma</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1466-9413</contrib-id>
          <name>
            <surname>Mesquita</surname>
            <given-names>Claudio Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Evandro Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Complexo Hospitalar de Niter&#243;i</institution>
        <addr-line>
          <city>Niter&#243;i</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Complexo Hospitalar de Niter&#243;i - Cardiologia, Niter&#243;i, RJ - Brazil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Hospital Universit&#225;rio Ant&#244;nio Pedro</institution>
        <institution content-type="orgdiv1">Departamento de Cardiologia (Ebserh/UFF)</institution>
        <addr-line>
          <city>Niter&#243;i</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital Universit&#225;rio Ant&#244;nio Pedro, Departamento de Cardiologia (Ebserh/UFF), Niter&#243;i, RJ - Brazil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgname">Labs a+ / Grupo Fleury RJ</institution>
        <addr-line>
          <city>Niter&#243;i</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Labs a+ / Grupo Fleury RJ - Ecocardiografia, Niter&#243;i, RJ - Brazil</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <addr-line>
          <city>Rio de Janeiro</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital Pr&#243;-Card&#237;aco - Medicina Nuclear, Rio de Janeiro, RJ - Brazil</institution>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <institution content-type="orgname">Hospital Universit&#225;rio Antonio Pedro</institution>
        <institution content-type="orgdiv1">Departamento de Radiologia (Ebserh/UFF)</institution>
        <addr-line>
          <city>Niter&#243;i</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital Universit&#225;rio Antonio Pedro, Departamento de Radiologia (Ebserh/UFF), Niteroi, Rio de Janeiro - Brazil</institution>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <institution content-type="orgname">Americas Medical City - Centro de Educa&#231;&#227;o e Treinamento Edson Bueno</institution>
        <addr-line>
          <city>Rio de Janeiro</city>
          <state>RJ</state>
        </addr-line>
        <country country="BR">Brazil</country>
        <institution content-type="original">Americas Medical City - Centro de Educa&#231;&#227;o e Treinamento Edson Bueno, Rio de Janeiro, RJ - Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c1"><bold>Mailing Address: N&#225;gela S. V. Nunes,</bold> Complexo Hospitalar de Niter&#243;i - Cardiologia - Rua La Sale, 12. Postal Code 24020-096, Centro, Niter&#243;i, RJ - Brazil. E-mail: <email>nvinhosa@me.com</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Author contributions</bold>
          </p>
          <p>Conception and design of the research and Acquisition of data: Nunes NSV, Mesquita CT, Mesquita ET; Analysis and interpretation of the data: Nunes NSV, Carvalho JPM, Costa FS, Nacif MS, Dominato J, Mesquita CT, Mesquita ET; Writing of the manuscript: Nunes NSV, Carvalho JPM, Costa FS, Nacif MS, Dominato J; Critical revision of the manuscript for intellectual content: Mesquita CT, Mesquita ET.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>14</day>
        <month>11</month>
        <year>2019</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2020</year>
      </pub-date>
      <volume>114</volume>
      <issue>4 suppl 1</issue>
      <fpage>1</fpage>
      <lpage>3</lpage>
      <history>
        <date date-type="received">
          <day>03</day>
          <month>08</month>
          <year>2018</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>12</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>12</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="en">
        <title>Keywords:</title>
        <kwd>Syncope</kwd>
        <kwd>Amyloidosis, Familial/genetics</kwd>
        <kwd>Amyloid Neuropathies, Familial</kwd>
        <kwd>Cardiomyopathies/diagnosis</kwd>
        <kwd>Diagnostic, Imaging/methods</kwd>
        <kwd>Prevalence</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Transthyretin amyloidosis (ATTR) is a familial disease caused by one of more than 100 described mutations, where there is production of amyloids that are deposited in tissues.<xref ref-type="bibr" rid="B1">1</xref> Phenocopies include neuropathy (autonomic and peripheral), cardiomyopathy, renal, gastrointestinal, vitreous and meningeal involvement, which vary according to the genetic mutation, ethnicity and geographical origin, even among individuals with the same mutation or within the same family.<xref ref-type="bibr" rid="B2">2</xref>
			</p>
      <p>Syncope (transient loss of consciousness caused by global cerebral hypoperfusion) in the presence of heart disease confers risk of fatal events.<xref ref-type="bibr" rid="B3">3</xref> The Val142Ile mutation has heart failure with preserved ejection fraction (HFpEF) as the predominant clinical phenotype, with syncope being an uncommon symptom.<xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B5">5</xref>
			</p>
    </sec>
    <sec sec-type="cases">
      <title>Case Report</title>
      <p>The patient was male, 64 years old, of white ethnicity, engineer, born in Rio de Janeiro. He reported an isolated episode of syncope when he quickly got up from a sitting position after running. There was a history of sudden death in the family (uncle at 60). He used to take escitalopram 10 mg/day and finasteride 5 mg/day.</p>
      <p>At physical examination: BMI of 21.8 kg/m<sup>2</sup> and jugular turgency at 45&#186;. BP: 140x80 mmHg, HR: 85 bpm, RR: 18 breaths per minute, fourth heart sound, sustained and palpable apex beat in the 6&#186; intercostal space at the hemiclavicular line, clear lungs and ankle edema. He was in NYHA FC I. Blood: BNP: 233 pg/mL (NV: up to 100 pg/mL) and ultra-sensitive Troponin: 0.135 ng/mL (NV: up to 0.01 ng/mL).</p>
      <p>The electrocardiogram (EKG) (<xref ref-type="fig" rid="f1">Fig.1</xref>) showed sinus rhythm, HR: 84bpm, right bundle branch block, low voltage in frontal leads, and an pseudo-infarct pattern in precordial leads.</p>
      <p>
        <fig id="f1">
          <label>Figure 1</label>
          <caption>
            <title>A) Electrocardiogram: Sinus rhythm, HR: 88 bpm, indeterminate QRS axis. P-wave in the frontal plane with increased duration (160 ms), with partial Bachmann&#8217;s bundle block and tricuspid P wave in D2, D3 and aVF; qR pattern in V1 and Morris index are observed in the horizontal plane, which means right and left atrial enlargement. Pseudo-infarct pattern in precordial leads and presence of low voltage in the frontal plane are also observed. B and C) Resting Cardiac MRI shows diffuse LVH, with areas of diffuse subendocardial late enhancement in the LV (arrows), atria, and interatrial septum. D and E) 99mTc-PYP myocardial scintigraphy showing intense radiotracer uptake in the myocardium (Grade 3).</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-114-4suppl1-0001-80130-gf01.jpg"/></fig>
      </p>
      <p>The transthoracic Echocardiogram (TTE) showed left ventricular hypertrophy (LVH) - septum = 16 mm and posterior wall = 13 mm - mitral flow with type II relaxation deficit and LA indexed volume: 87 mL/m<sup>2</sup> (<xref ref-type="fig" rid="f2">Figure 2</xref>). 24-h Holter and Exercise Test (ET) showed short and asymptomatic polymorphic ventricular tachycardia (PVT) outbreaks.</p>
      <p>
        <fig id="f2">
          <label>Figure 2</label>
          <caption>
            <title>Transthoracic echocardiogram showing pseudonormal mitral Doppler pattern (type II diastolic dysfunction), tricuspid regurgitation peak velocity &gt;2.8 m/s and biatrial enlargement with indexed LA volume of 87 mL/m<sup>2</sup>. Parasternal longitudinal apical-4 chamber projections showing increased myocardial brightness, interatrial septum and valve thickening, and LVH. Global Longitudinal Strain showing typical amyloidosis pattern - &#8220;relative preservation of the apical regions&#8221; and longitudinal strain reduction in the basal and middle myocardial segments.</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-114-4suppl1-0001-80130-gf02.jpg"/></fig>
      </p>
      <p>Cardiac magnetic resonance imaging (CMRI) at rest and after stress with dipyridamole requested after TTE showed diffuse LVH and absence of myocardial ischemia, with areas of lateral and anterior mesocardial late enhancement (LE) and diffuse subendocardial LE in the LV, atria and interatrial septum (<xref ref-type="fig" rid="f1">Figure 1</xref>). Evaluation of global longitudinal strain (GLS) after CMRI showed marked alterations in the basal and medial portions of all myocardial walls, sparing the LV apical regions, which was consistent with the described cardiac amyloidosis (CA) pattern.</p>
      <p>Abdominal fat and rectal biopsies confirmed the diagnosis of amyloidosis with Congo red staining. Immunofixation in blood and 24-h urine and measurement of light chains Imunoglobulins in the blood ruled out monoclonal gammopathy, after which cardiac technetium-99m pyrophosphate scintigraphy (99mTc-PYP) (<xref ref-type="fig" rid="f1">Figure 1</xref>) was requested, witch showed intense radiotracer uptake in the myocardium (grade 3), suggesting Transthyretin CA (ATTR-CA) etiology.</p>
      <p>Finally, the patient underwent genetic testing, which confirmed a heterozygous Val142Ile mutation for the TTR gene.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>When evaluating a syncope patient, it is a priority to stratify the risk of fatal events,<xref ref-type="bibr" rid="B3">3</xref> which take into account electro and echocardiographic alterations, which were present in this patient. The low voltage pattern found in the EKG (<xref ref-type="fig" rid="f1">Figure 1</xref>), in the presence of LVH, are already warning signs for the diagnosis of CA.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B6">6</xref>
			</p>
      <p>Elevated BNP and troponin levels reflected increased intracavitary pressures and ongoing myocardial injury, which was indicative of heart disease.</p>
      <p>The TTE confirmed the suspected heart disease. The (<xref ref-type="fig" rid="f2">Figure 2</xref>), family history of sudden death and the presence of PVT on exertion raised the suspicion of cardiac syncope and the main differential diagnoses would be hypertrophic cardiomyopathy (HCM), coronary artery disease (CAD) and CA.<xref ref-type="bibr" rid="B3">3</xref>
			</p>
      <p>The CMRI, which was subsequently requested, provided evidence that was strongly suggestive of CA, given the characteristic LE pattern, ruling out the hypotheses of HCM and CAD. Because gadolinium is a purely extracellular agent and does not penetrate the intact cardiomyocyte, the characteristic appearance of LE (<xref ref-type="fig" rid="f1">Figure1</xref>) in non-coronary territory is extremely suggestive of CA and this was decisive in this case.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B7">7</xref>
			</p>
      <p>The evaluation of myocardial deformity by the GLS technique, performed after the CMRI, demonstrated a typical pattern of CA (<xref ref-type="fig" rid="f2">Figure 2</xref>), which ruled out other causes of LVH and corroborated the diagnosis, which has been very useful in this scenario.<xref ref-type="bibr" rid="B8">8</xref>
			</p>
      <p>Among the CA types, the one caused by light chains Imunoglobulins (AL) is the one that most commonly affects the heart; therefore, we began with the search for hematological disease.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B6">6</xref> Since the definitive diagnosis of CA required tissue biopsy at that time, this was performed. More recent diagnostic algorithms reserve tissue biopsy only for suspected cases of AL, as the 99m-Tc-PYP myocardial scintigraphy replaced myocardial biopsy in ATTR-CA.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B9">9</xref>
			</p>
      <p>This technique has been used for a long time to diagnose bone diseases, of which radiotracer has a strong affinity for calcium, that is almost only present in ATTR deposits. Positive and negative predictive values for ATTR diagnosis by 99mTc-PYP myocardial scintigraphy with a score &#8805; 2 are 88 and 100%, respectively. Diagnostic certainty is proposed when the score is &#8805; 2 in the absence of an immunoglobulin monoclonal peak, which would be equivalent to a positive endomyocardial biopsy,<xref ref-type="bibr" rid="B9">9</xref> as in the case described (<xref ref-type="fig" rid="f1">Figure1</xref>), witch was confirmed latter by the genetic testing.</p>
      <p>The most frequent cardiac symptoms in Val142Ile ATTR are: heart failure, dyspnea, arrhythmias and dizziness. Syncope, most frequently found in AL (20%), is unusual in ATTR (8%), and when it occurs on exertion it represents the inability to increase cardiac output, which confers high mortality.<xref ref-type="bibr" rid="B5">5</xref><sup>,</sup><xref ref-type="bibr" rid="B10">10</xref> Moreover, sensitivity to intravascular fluid depletion combined with autonomic neuropathy, depressed myocardial reserve, atrial dysfunction and stiffness, and the presence of arrhythmias contribute to the occurrence of syncope.<xref ref-type="bibr" rid="B6">6</xref> All these possibilities make syncope a multifactorial presentation in CA, as it may have occurred in the case described herein.</p>
      <p>THAOS, an open worldwid registry to all patients with ATTR, shows that the Val142Ile, also known as Val122Ile mutation, is the second most common genotype worldwide and the most common in the USA, accounting for 23% of the total mutations in the country and 1% in the rest of the world. The carriers of this mutation are mostly of African descent and males, being prevalent in 3 to 4% of African-Americans at birth, with a penetrance of approximately 20%.<xref ref-type="bibr" rid="B5">5</xref>
			</p>
      <p>ATTR is an underdiagnosed cause of HFpEF, although TTR deposits are identified in up to 30% of elderly patients referred for autopsy.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B2">2</xref><sup>,</sup><xref ref-type="bibr" rid="B5">5</xref> Syncope, although uncommon in the presentation of this phenotype, may be the first symptom of this disease.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Ethics approval and consent to participate</bold>
        </p>
        <p>This article does not contain any studies with human participants or animals performed by any of the authors.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nativi-Nicolau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Amyloidosis cardiomyopathy</article-title>
          <source>Curr Opin Cardiol</source>
          <year>2018</year>
          <volume>33</volume>
          <issue>5</issue>
          <fpage>571</fpage>
          <lpage>579</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2 Ando Y, Coelho T, Berk JL, Waddington Cruz M, Ericzon B-G, Ikeda S-I, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ando</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Berk</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Waddington Cruz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ericzon</surname>
              <given-names>B-G</given-names>
            </name>
            <name>
              <surname>Ikeda</surname>
              <given-names>S-I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guideline of transthyretin-related hereditary amyloidosis for clinicians</article-title>
          <source>Orphanet J Rare Dis</source>
          <day>20</day>
          <month>02</month>
          <year>2013</year>
          <volume>8</volume>
          <fpage>31</fpage>
          <lpage>31</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3 Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brignole</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Lange</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Deharo</surname>
              <given-names>J-C</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Fanciulli</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2018 ESC Guidelines for the diagnosis and management of syncope</article-title>
          <source>Eur Heart J</source>
          <year>2018</year>
          <volume>39</volume>
          <issue>21</issue>
          <fpage>1883</fpage>
          <lpage>1948</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4 Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis</article-title>
          <source>Circulation</source>
          <year>2017</year>
          <volume>135</volume>
          <issue>14</issue>
          <fpage>1357</fpage>
          <lpage>1377</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maurer</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Hanna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dispenzieri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Witteles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Drachman</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genotype and Phenotype of Transthyretin Cardiac Amyloidosis</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2016</year>
          <volume>68</volume>
          <issue>2</issue>
          <fpage>161</fpage>
          <lpage>172</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;(2):1-13.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Banypersad</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Whelan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Wechalekar</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Updates in Cardiac Amyloidosis: A Review</article-title>
          <source>J Am Heart Assoc</source>
          <year>2012</year>
          <issue>2</issue>
          <fpage>1</fpage>
          <lpage>13</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7 Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466-77.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez-Naharro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Treibel</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Abdel-Gadir</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bulluck</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zumbo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>DS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Magnetic Resonance in Transthyretin Cardiac Amyloidosis</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2017</year>
          <volume>70</volume>
          <issue>4</issue>
          <fpage>466</fpage>
          <lpage>477</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8 Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, et al. Application of a Parametric Display of Two-Dimensional Speckle-Tracking Longitudinal Strain to Improve the Etiologic Diagnosis of Mild to Moderate Left Ventricular Hypertrophy. J Am Soc Echocardiogr. 2014; 27(8):888-95.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phelan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Thavendiranathan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Popovic</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Collier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Application of a Parametric Display of Two-Dimensional Speckle-Tracking Longitudinal Strain to Improve the Etiologic Diagnosis of Mild to Moderate Left Ventricular Hypertrophy</article-title>
          <source>J Am Soc Echocardiogr</source>
          <year>2014</year>
          <volume>27</volume>
          <issue>8</issue>
          <fpage>888</fpage>
          <lpage>895</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9 Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillmore</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Falk</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Damy</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dispenzieri</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nonbiopsy diagnosis of cardiac transthyretin amyloidosis</article-title>
          <source>Circulation</source>
          <year>2016</year>
          <volume>133</volume>
          <issue>24</issue>
          <fpage>2404</fpage>
          <lpage>2412</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10 Marin-Acevedo JA, Sanchez-Alvarez C, Alsaad AA, Pag&#225;n RJ. Case Report Recurrent syncope, a clue in amyloid cardiomyopathy. Case Rep Med. 2018 Jan 28:1-6.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marin-Acevedo</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sanchez-Alvarez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Alsaad</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Pag&#225;n</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Case Report Recurrent syncope, a clue in amyloid cardiomyopathy</article-title>
          <source>Case Rep Med</source>
          <day>28</day>
          <month>01</month>
          <year>2018</year>
          <fpage>1</fpage>
          <lpage>6</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="s1" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>S&#237;ncope como Express&#227;o Fenot&#237;pica da Amiloidose Heredit&#225;ria por Transtirretina Val142Ile (Val122Ile)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-2814-8395</contrib-id>
          <name>
            <surname>Nunes</surname>
            <given-names>N&#225;gela S. V.</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">1</xref>
          <xref ref-type="aff" rid="aff8">2</xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Jo&#227;o Paulo Moreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Costa</surname>
            <given-names>Fernanda Salom&#227;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-2791-8375</contrib-id>
          <name>
            <surname>Nacif</surname>
            <given-names>Marcelo Souto</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">1</xref>
          <xref ref-type="aff" rid="aff11">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dominato</surname>
            <given-names>Joelma</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-1466-9413</contrib-id>
          <name>
            <surname>Mesquita</surname>
            <given-names>Claudio Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">4</xref>
          <xref ref-type="aff" rid="aff11">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Evandro Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">2</xref>
          <xref ref-type="aff" rid="aff12">6</xref>
        </contrib>
      </contrib-group>
      <aff id="aff7">
        <label>1</label>
        <institution content-type="original">Complexo Hospitalar de Niter&#243;i - Cardiologia, Niter&#243;i, RJ - Brasil</institution>
      </aff>
      <aff id="aff8">
        <label>2</label>
        <institution content-type="original">Hospital Universit&#225;rio Ant&#244;nio Pedro, Departamento de Cardiologia (Ebserh/UFF), Niter&#243;i, RJ - Brasil</institution>
      </aff>
      <aff id="aff9">
        <label>3</label>
        <institution content-type="original">Labs a+ / Grupo Fleury RJ - Ecocardiografia, Niter&#243;i, RJ - Brasil</institution>
      </aff>
      <aff id="aff10">
        <label>4</label>
        <institution content-type="original">Hospital Pr&#243;-Card&#237;aco - Medicina Nuclear, Rio de Janeiro, RJ - Brasil</institution>
      </aff>
      <aff id="aff11">
        <label>5</label>
        <institution content-type="original">Hospital Universit&#225;rio Antonio Pedro, Departamento de Radiologia (Ebserh/UFF), Niteroi, Rio de Janeiro - Brasil</institution>
      </aff>
      <aff id="aff12">
        <label>6</label>
        <institution content-type="original">Americas Medical City - Centro de Educa&#231;&#227;o e Treinamento Edson Bueno, Rio de Janeiro, RJ - Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c2"><bold>Correspond&#234;ncia: N&#225;gela S. V. Nunes,</bold> Complexo Hospitalar de Niter&#243;i - Cardiologia - Rua La Sale, 12. CEP 24020-096, Centro, Niter&#243;i, RJ - Brasil. E-mail: <email>nvinhosa@me.com</email>
				</corresp>
        <fn fn-type="con">
          <p>
            <bold>Contribui&#231;&#227;o dos autores</bold>
          </p>
          <p>Concep&#231;&#227;o e desenho da pesquisa e Obten&#231;&#227;o de dados: Nunes NSV, Mesquita CT, Mesquita ET; An&#225;lise e interpreta&#231;&#227;o dos dados: Nunes NSV, Carvalho JPM, Costa FS, Nacif MS, Dominato J, Mesquita CT, Mesquita ET; Reda&#231;&#227;o do manuscrito: Nunes NSV, Carvalho JPM, Costa FS, Nacif MS; Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante: Mesquita CT, Mesquita ET.</p>
        </fn>
        <fn fn-type="conflict">
          <p>
            <bold>Potencial conflito de interesses</bold>
          </p>
          <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave:</title>
        <kwd>S&#237;ncope</kwd>
        <kwd>Amiloidose Familiar/gen&#233;tica</kwd>
        <kwd>Neuropatias Amiloides Familiares</kwd>
        <kwd>Cardiomiopatias/diagn&#243;stico</kwd>
        <kwd>Diagn&#243;stico por Imagem/m&#233;todos</kwd>
        <kwd>Preval&#234;ncia.</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introdu&#231;&#227;o</title>
        <p>A amiloidose por transtirretina (ATTR) &#233; uma doen&#231;a familiar causada por uma das mais de 100 muta&#231;&#245;es descritas, em que h&#225; produ&#231;&#227;o de amiloides que se depositam nos tecidos.<xref ref-type="bibr" rid="B1">1</xref> As fenoc&#243;pias abrangem neuropatia (auton&#244;mica e perif&#233;rica), cardiomiopatia, acometimento renal, gastrointestinal, de v&#237;treo e de meninge, que variam de acordo com a muta&#231;&#227;o gen&#233;tica, etnia e origem geogr&#225;fica, mesmo entre indiv&#237;duos com a mesma muta&#231;&#227;o ou dentro da mesma fam&#237;lia.<xref ref-type="bibr" rid="B2">2</xref>
				</p>
        <p>A s&#237;ncope (perda transit&#243;ria da consci&#234;ncia causada por hipoperfus&#227;o cerebral global) na presen&#231;a de cardiopatia, confere risco de eventos fatais.<xref ref-type="bibr" rid="B3">3</xref> A muta&#231;&#227;o Val142Ile tem a insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o preservada (ICFEP) como fen&#243;tipo cl&#237;nico predominante, sendo a s&#237;ncope um sintoma pouco comum.<xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B5">5</xref>
				</p>
      </sec>
      <sec sec-type="cases">
        <title>Relato do Caso</title>
        <p>Homem, 64 anos, branco, engenheiro, natural do Rio de Janeiro. Relatava epis&#243;dio isolado de s&#237;ncope ao levantar-se r&#225;pido da posi&#231;&#227;o sentada, ap&#243;s corrida. Hist&#243;rico de morte s&#250;bita na fam&#237;lia (tio aos 60 anos). Usava escitalopram 10 mg/dia e finasterida 5 mg/dia.</p>
        <p>Exame f&#237;sico: IMC de 21,8 Kg/m<sup>2</sup> e turg&#234;ncia jugular a 45&#186;. PA: 140x80 mmHg, FC: 85 bpm, FR: 18 ipm, quarta bulha, ictus sustido e palp&#225;vel no 6&#186; espa&#231;o intercostal na linha hemiclavicular, pulm&#245;es limpos e edema de tornozelos. Vinha em CF I.</p>
        <p>Sangue: pept&#237;deo natriur&#233;tico do tipo B (BNP): 233 pg/ml (VN: at&#233; 100 pg/ml) e Troponina US: 0,135 ng/ml (VN: at&#233; 0,01 ng/ml).</p>
        <p>Eletrocardiograma (ECG) (<xref ref-type="fig" rid="f3">Figura 1</xref>): ritmo sinusal, FC: 84 bpm, bloqueio de ramo direito, baixa voltagem nas deriva&#231;&#245;es frontais e amputa&#231;&#227;o de R anterosseptal.</p>
        <p>
          <fig id="f3">
            <label>Figura 1</label>
            <caption>
              <title>A) Eletrocardiograma: Ritmo sinusal, FC: 88 bpm, eixo do QRS indeterminado. Onda P no plano frontal com dura&#231;&#227;o aumentada (160 ms), com bloqueio parcial do feixe de Bachmann e onda P tricusp&#237;dea em D2, D3 e aVF; e no plano horizontal observa-se padr&#227;o qR em V1 e &#237;ndice de Morris, o que traduz aumento dos &#225;trios direito e esquerdo. Observa-se tamb&#233;m amputa&#231;&#227;o de R anterosseptal e presen&#231;a de baixa voltagem no plano frontal. B e C) Resson&#226;ncia magn&#233;tica do cora&#231;&#227;o em repouso mostra HVE difusa, com &#225;reas de realce tardio subendoc&#225;rdico difuso no VE (setas), nos &#225;trios e no septo interatrial. D e E) Cintilografia mioc&#225;rdica com Pirofosfato de 99m-Tecn&#233;cio mostrando intensa fixa&#231;&#227;o do radiotra&#231;ador no mioc&#225;rdio (escore grau 3).</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-114-4suppl1-0001-80130-gf01-pt.jpg"/></fig>
        </p>
        <p>Ecocardiograma (ECO TT): hipertrofia ventricular esquerda (HVE) - septo = 16 mm e parede posterior = 13 mm - fluxo mitral com d&#233;ficit de relaxamento tipo II e volume indexado do &#225;trio esquerdo: 87 ml/m<sup>2</sup> (<xref ref-type="fig" rid="f4">Figura 2</xref>). Holter de 24 h e teste ergom&#233;trico apresentavam surtos curtos e assintom&#225;ticos de taquicardia ventricular polim&#243;rfica (TVP).</p>
        <p>
          <fig id="f4">
            <label>Figura 2</label>
            <caption>
              <title>Ecocardiograma transtor&#225;cico mostrando padr&#227;o do Doppler mitral do tipo pseudonormal (disfun&#231;&#227;o diast&#243;lica tipo II), pico de velocidade da insufici&#234;ncia tric&#250;spide &gt; 2,8 m/s e aumento biatrial com volume indexado do &#225;trio esquerdo de 87 ml/m<sup>2</sup>. Cortes longitudinal paraesternal e apical 4 c&#226;maras mostrando aumento do brilho mioc&#225;rdico, espessamento do septo interatrial e das valvas e HVE. Strain global longitudinal com padr&#227;o t&#237;pico de amiloidose - "relativa preserva&#231;&#227;o das regi&#245;es apicais" e redu&#231;&#227;o do strain longitudinal nos segmentos basal e m&#233;dio do mioc&#225;rdio.</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-114-4suppl1-0001-80130-gf02-pt.jpg"/></fig>
        </p>
        <p>Solicitada resson&#226;ncia magn&#233;tica do cora&#231;&#227;o (RMC) em repouso e ap&#243;s estresse com dipiridamol, que mostrou HVE difusa e aus&#234;ncia de isquemia mioc&#225;rdica, com &#225;reas de realce tardio (RT) mesoc&#225;rdico lateral e anterior e subendoc&#225;rdico difuso no ventr&#237;culo esquerdo (VE), nos &#225;trios e no septo interatrial (<xref ref-type="fig" rid="f3">Figura 1</xref>). Avalia&#231;&#227;o do <italic>strain</italic> global longitudinal (SGL), ap&#243;s RMC, mostrou altera&#231;&#245;es marcadas nas por&#231;&#245;es basal e medial de todas as paredes do mioc&#225;rdio, poupando as regi&#245;es apicais do VE, o que era compat&#237;vel com padr&#227;o descrito de amiloidose card&#237;aca (AC).</p>
        <p>A bi&#243;psia de gordura abdominal e reto confirmaram o diagn&#243;stico de amiloidose, pela colora&#231;&#227;o vermelho congo. Imunofixa&#231;&#227;o no sangue e na urina de 24 horas e dosagem de cadeias leves no sangue afastaram gamopatia monoclonal, sendo solicitada, ap&#243;s isso, cintilografia mioc&#225;rdica (CM) Pirofosfato de 99m-Tecn&#233;cio (<xref ref-type="fig" rid="f3">Figura 1</xref>), que mostrou intensa fixa&#231;&#227;o do radiotra&#231;ador no mioc&#225;rdio (escore grau 3), sugerindo ser a etiologia da AC do tipo ATTR.</p>
        <p>Por fim, o paciente foi submetido a teste gen&#233;tico, o qual confirmou muta&#231;&#227;o em heterozigose para o gene da transtirretina (TTR) do tipo Val142Ile.</p>
      </sec>
      <sec sec-type="discussion">
        <title>Discuss&#227;o</title>
        <p>Quando se avalia um paciente v&#237;tima de s&#237;ncope, &#233; priorit&#225;ria a estratifica&#231;&#227;o do risco de eventos fatais,<xref ref-type="bibr" rid="B3">3</xref> que levam em conta altera&#231;&#245;es eletro e ecocardiogr&#225;ficas, as quais estavam presentes neste paciente. As altera&#231;&#245;es encontradas no ECG (<xref ref-type="fig" rid="f3">Figura 1</xref>), na presen&#231;a de HVE, j&#225; s&#227;o sinais de alerta para o diagn&#243;stico de AC.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B6">6</xref>
				</p>
        <p>O BNP e a troponina elevados traduziam aumento de press&#245;es intracavit&#225;rias e inj&#250;ria mioc&#225;rdica em curso, o que era indicativo de doen&#231;a card&#237;aca.</p>
        <p>O ECO TT confirmou a suspeita de cardiopatia. As altera&#231;&#245;es encontradas (<xref ref-type="fig" rid="f4">Figura 2</xref>), a hist&#243;ria familiar de morte s&#250;bita e TVP ao esfor&#231;o, levantaram suspeita de s&#237;ncope card&#237;aca e os diagn&#243;sticos diferenciais principais seriam miocardiopatia hipertr&#243;fica (MCPH), doen&#231;a arterial coronariana (DAC) e AC.<xref ref-type="bibr" rid="B3">3</xref>
				</p>
        <p>A RMC, solicitada a seguir, forneceu evid&#234;ncias fortemente sugestivas de AC, dado ao padr&#227;o caracter&#237;stico do RT, afastando as hip&#243;teses de MCPH e de DAC. Por ser o gadol&#237;neo um agente puramente extracelular e n&#227;o penetrar no cardiomi&#243;cito intacto, a apar&#234;ncia caracter&#237;stica do RT (<xref ref-type="fig" rid="f3">Figura 1</xref>) em territ&#243;rio n&#227;o coronariano &#233; extremamente sugestiva de AC e foi determinante no caso relatado.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B7">7</xref>
				</p>
        <p>A avalia&#231;&#227;o da deformidade mioc&#225;rdica pela t&#233;cnica do SGL, realizada ap&#243;s a RMC, demonstrou um padr&#227;o t&#237;pico de AC (<xref ref-type="fig" rid="f4">Figura 2</xref>), o que p&#244;de descartar outras causas de HVE e corroborar o diagn&#243;stico, o que tem sido muito &#250;til neste cen&#225;rio.<xref ref-type="bibr" rid="B8">8</xref>
				</p>
        <p>Dentre os tipos de AC, a causada por cadeias leves de imunoglobulina (AL) &#233; a que mais comumente acomete o cora&#231;&#227;o, por isso, inicia-se a investiga&#231;&#227;o pela busca de doen&#231;a hematol&#243;gica.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B4">4</xref><sup>,</sup><xref ref-type="bibr" rid="B6">6</xref> Como o diagn&#243;stico definitivo de AC requeria, &#224; &#233;poca, bi&#243;psia tissular, assim foi feito. Algoritmos diagn&#243;sticos mais recentes reservam a bi&#243;psia tissular apenas para os casos suspeitos de AL, j&#225; que a CM com Pirofosfato de 99m-Tecn&#233;cio substitui a bi&#243;psia mioc&#225;rdica na ATTR.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B9">9</xref>
				</p>
        <p>Essa t&#233;cnica &#233; usada h&#225; tempos para diagn&#243;stico de patologias &#243;sseas, cujo radiotra&#231;ador tem grande afinidade pelo c&#225;lcio, o qual est&#225; presente, quase sempre, apenas nos dep&#243;sitos da ATTR. Os valores preditivos positivos e negativos para o diagn&#243;stico de ATTR pela CM com escore &#8805; 2 &#233; de 88 e 100% respectivamente. Prop&#245;e-se certeza diagn&#243;stica quando h&#225; escore &#8805; 2 na aus&#234;ncia de pico monoclonal de imunoglobulina, o que equivaleria &#224; bi&#243;psia endomioc&#225;rdica,<xref ref-type="bibr" rid="B9">9</xref> como aconteceu no caso descrito (<xref ref-type="fig" rid="f3">Figura 1</xref>), confirmado pelo teste gen&#233;tico.</p>
        <p>Os sintomas cardiol&#243;gicos mais frequentes na ATTR Val142Ile s&#227;o: insufici&#234;ncia card&#237;aca, dispneia, arritmias e tonteira. S&#237;ncope &#233; um achado incomum (8%), mais frequente AL (20%), e quando acontece no esfor&#231;o representa a inabilidade em aumentar o d&#233;bito card&#237;aco, o que confere alta mortalidade.<xref ref-type="bibr" rid="B5">5</xref><sup>,</sup><xref ref-type="bibr" rid="B10">10</xref> Al&#233;m disso contribuem para a ocorr&#234;ncia de s&#237;ncope, a sensibilidade a deple&#231;&#227;o de fluidos do intravascular combinada a neuropatia auton&#244;mica, reserva mioc&#225;rdica deprimida, disfun&#231;&#227;o e rigidez atrial e a presen&#231;a de arritmias.<xref ref-type="bibr" rid="B6">6</xref> Todas essas possibilidades fazem da s&#237;ncope uma apresenta&#231;&#227;o multifatorial na AC, como pode ter ocorrido no caso descrito.</p>
        <p>O THAOS, um registro mundial, aberto a todos os pacientes portadores de ATTR, mostra que a muta&#231;&#227;o Val142Ile (tamb&#233;m conhecida como Val122Ile) &#233; a segunda muta&#231;&#227;o mais comum no mundo e a mais comum nos EUA, contabilizando 23% do total neste pa&#237;s e 1% do resto do mundo. Os portadores dessa muta&#231;&#227;o s&#227;o, em sua maioria, afrodescendentes e homens, sendo prevalente em 3 a 4% de afroamericanos ao nascerem, com penetr&#226;ncia de aproximadamente 20%.<xref ref-type="bibr" rid="B5">5</xref>
				</p>
        <p>A ATTR &#233; uma causa subdiagnosticada de ICFEP, embora dep&#243;sitos de TTR sejam identificados em at&#233; 30% de idosos encaminhados a aut&#243;psia.<xref ref-type="bibr" rid="B1">1</xref><sup>,</sup><xref ref-type="bibr" rid="B2">2</xref><sup>,</sup><xref ref-type="bibr" rid="B5">5</xref> S&#237;ncope apesar de incomum na apresenta&#231;&#227;o desse fen&#243;tipo, pode ser o primeiro sintoma dessa enfermidade.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="financial-disclosure">
          <p>
            <bold>Fontes de financiamento</bold>
          </p>
          <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
        </fn>
        <fn fn-type="other">
          <p>
            <bold>Vincula&#231;&#227;o acad&#234;mica</bold>
          </p>
          <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
        </fn>
        <fn fn-type="other">
          <p>
            <bold>Aprova&#231;&#227;o &#233;tica e consentimento informado</bold>
          </p>
          <p>Este artigo n&#227;o cont&#233;m estudos com humanos ou animais realizados por nenhum dos autores.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
